Market Place
Sourcing Support
Trevi’s CORAL Trial Maintains Sample Size For Chronic Cough In IPF
12 Dec 2024 //
PR NEWSWIRE
Trevi Shows Positive Results in Oral Nalbuphine Abuse Study
03 Dec 2024 //
PR NEWSWIRE
Trevi Completes Enrollment For Phase 2a RIVER Cough Trial in Cough
21 Oct 2024 //
PR NEWSWIRE
Trevi To Present CANAL Trial Data At CHEST 2024
26 Sep 2024 //
PR NEWSWIRE
Somerset`s Generics Nalbuphine HCl Receives Approval in US
19 Sep 2024 //
FDA
Trevi Therapeutics to Participate in September Investor and Medical Conferences
28 Aug 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
02 Jul 2024 //
PR NEWSWIRE
Trevi Therapeutics to Participate in Upcoming April Events
04 Apr 2024 //
PR NEWSWIRE
Trevi Adds Clinical Development Expertise in Chronic Cough to Leadership Team
02 Apr 2024 //
PR NEWSWIRE
Trevi Adds Clinical Devp Expertise in Chronic Cough to Leadership Team
02 Apr 2024 //
BIOSPACE
Trevi Therapeutics Announces 1Q 2023FYR &Provides Business Update
11 May 2023 //
PR NEWSWIRE
Enforcement Report - Week of February 22, 2023
22 Feb 2023 //
FDA
Trevi reports positive Phase II data of Haduvio for chronic cough in IDF
19 Sep 2022 //
CLINICALTRIALSARENA
Trevi Tx Announces Multiple Late-Breaking Abstracts Accepted for Presentation
24 Aug 2022 //
PRNEWSWIRE
Trevi Tx Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus
01 Feb 2022 //
PRNEWSWIRE
Trevi Therapeutics Announces Q3 2021 Financial Results and Business Update
10 Nov 2021 //
PRNEWSWIRE
Trevi Therapeutics Announces $11.8M Private Placement Priced At-the-Market
30 Sep 2021 //
PRNEWSWIRE
Trevi Therapeutics Announces Election of Dominick C. Colangelo to BOD
30 Jun 2020 //
GLOBENEWSWIRE
Lumosa Announces FDA Acceptance of IND Application for LT1001
03 Dec 2019 //
PR NEWSWIRE
Spectrum Laboratory Products Receives FDA Warning Letter
04 Jun 2019 //
FDA
Mylan Labs` Generic Nalbuphine Hydrochloride Receives Approval in US
08 Feb 2019 //
FDA
Trevi Therapeutics Announces License Agreements for use of Nalbuphine
04 Feb 2019 //
BUSINESSWIRE
Trevi Therapeutics Initiates Clinical Trial of Nalbuphine in Prurigo Nodularis
27 Sep 2018 //
BUSINESSWIRE
Drug shortages become issue in Teva and Mylan hook-up
30 Apr 2015 //
FIERCE PHARMA MANUFACTURING
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.